ArticleNorthern clinics of Istanbul2024
Effect of latanoprost on choroidal thickness in patients with newly diagnosed primary open-angle glaucoma.
Article in Northern clinics of Istanbul, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe purpose of this study was to assess the influence of latanoprost on choroidal thickness in patients with newly diagnosed primary open-angle glaucoma using Swept-Source Optical Coherence Tomography (SS-OCT).
methodsThe retrospective, non-randomized study comprised 40 newly diagnosed primary open-angle glaucoma patients receiving latanoprost therapy (Group 1). Additionally, 40 age- and sex-matched healthy subjects served as the control group (Group 2). Using SS-OCT, measurements of subfoveal, horizontal temporal, and horizontal nasal quadrants choroidal thickness, as well as intraocular pressure (IOP) and retinal nerve fiber layer (RNFL) thickness values, were collected at baseline and after 1 month for both groups.
resultsThe mean age was 39.8±4.15 years (range: 18-45 years) in group 1 and 41.67±7.95 years (range: 18-45 years) in group 2 (p>0.05). The mean choroidal thickness in the subfoveal area, horizontal temporal quadrant, and horizontal nasal quadrant prior to latanoprost therapy were 263.57±84.23 μm, 233.05±80.08 μm, and 219.52±83.28 μm in the group 1 whereas 278.9±93.88 μm, 243.8±73.37 μm and 209.85±92.92 μm in the group 2. After latanoprost therapy, the mean choroidal thickness in the subfoveal area, horizontal temporal quadrant, and horizontal nasal quadrant changed significantly to 299.77±41.29 μm, 269.9±43.80 μm, and 261.32±45.60 μm in the group 1 (p=0.02, p=0.016, and p=0.012, respectively) (Table 1). However, the mean choroidal thickness in the subfoveal area, horizontal temporal quadrant and horizontal nasal quadrant in group 2 changed not significant and was 279.25±103.37 μm, 246.42±87.07 μm and 203.62±106.74 μm, respectively (p=0.4, p=0.5 and p=0.9, respectively). The mean IOP decreased significantly in group 1 (p=0.000) but did not change significantly in group 2 (p=0.153). There was no difference in RNFL thickness values at baseline and 1 st month in group 1 and group 2 (p>0.05).
conclusionTopical latanoprost may increase choroidal thickness. Swept Source-OCT may contribute to our understanding of the actions of latanoprost on choroidal thickness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.